Vinblastine Sulfate (Vinblastine Sulfate) Patent Expiration, LOE Window & CMS Spending

Vinblastine Sulfate (Vinblastine Sulfate) by App/Fresenius K: Multi-Source Generic Molecule, 0 AB generics, $659K 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorApp/Fresenius K
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$659K
2024 Medicare Part D Spend$2K
2024 Medicaid Spend$657K
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 24.8% 2-yr change)